Chronic graft-versus-host disease in children and adolescents after bone marrow transplantation from HLA-matched donors.
We analyzed 98 pediatric patients who underwent bone marrow transplantation (BMT) from serologically HLA-matched related donors (RD) or unrelated donors (UD) at our institute to clarify the actual status of chronic graft-versus-host disease (cGVHD). There were 36 evaluable cases of RD-BMT and 35 of UD-BMT. cGVHD was observed in 8 RD-BMT cases (22.2%) and in 23 UD-BMT cases (65.7%). In the RD-BMT cases, the limited and extensive types of cGVHD were observed in 4 cases each, whereas in the UD-BMT cases, the limited type was seen in 11 cases and the extensive type in 12. Prior acute GVHD was observed in 6 RD-BMT cases and in 18 UD-BMT cases. Two RD-BMT patients with extensive type cGVHD died of relapse and cytomegalovirus infection, and 4 UD-BMT patients died because of bronchiolitis obliterans, fungal infection, liver failure, and multiple organ failure, respectively. The incidence of cGVHD in these pediatric patients was as high as that in adult patients when UD-BMT was performed. Some UD-BMT patients required long-term immunosuppressive therapy after BMT. These findings suggest that cGVHD is a serious problem in pediatric UD-BMT. Therefore, intensive prophylaxis and treatment of GVHD must always be performed after UD-BMT.
Yumura-Yagi
K
K
Department of Pediatrics, Osaka Medical Center, Japan.
Inoue
M
M
Sakata
N
N
Okamura
T
T
Yasui
M
M
Nakano
T
T
Nomura
K
K
Nakano
T
T
Park
D Y
DY
Endo
C
C
Nishiuchi
R
R
Sawada
A
A
Matsuda
Y
Y
Oota
H
H
Yoshimoto
T
T
Kawa-Ha
K
K
D000293:Adolescent; D000328:Adult; D016026:Bone Marrow Transplantation / Q000009:adverse effects*; D002648:Child; D002675:Child, Preschool; D002908:Chronic Disease; D005260:Female; D006086:Graft vs Host Disease / Q000453:epidemiology / Q000276:immunology*; D006650:Histocompatibility Testing; D006801:Humans; D015994:Incidence; D007223:Infant; D008297:Male; D009928:Organ Specificity; D012307:Risk Factors; D014019:Tissue Donors; D014184:Transplantation, Homologous / Q000009:adverse effects; D016896:Treatment Outcome